Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financi...( Conference Call To Be Held Thursday ...),Health

Conference Call To Be Held Thursday, August 14, 2008 at 9:00 a.m. Eastern

Time

HOPKINTON, Mass., Aug. 13 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reports operational and financial results for the quarter ended June 30, 2008 and provides further information for fiscal year 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

"Alseres made solid progress in our programs during the second quarter," commented Peter Savas, Chairman and Chief Executive Officer of Alseres. "To strengthen our molecular imaging efforts we have added the expertise of Dr. Thomas Tulip, previously with Lantheus Medical Imaging, Inc. (formerly Bristol Myers Squibb Medical Imaging). Enrollment continues to increase for the first phase of the Altropane POET-2 program. Recently, Lundbeck's partner Teva Pharmaceutical Industries, Ltd. announced the successful completion of ADAGIO, the phase III trial designed to demonstrate that Azilect(R) can slow the progression of Parkinson's disease. We believe that disease modifying drugs have the potential to significantly increase the use of Altropane if approved. We believe all of this has resulted in heightened interest from prospective partners in the potential for Altropane to provide fundamental changes in clinical outcomes for the 11 million Americans living with tremor disorders that are today misdiagnosed up to 35-50% of the time. We also anticipate the initiation of the streamlined Phase IIb trial of Cethrin. We believe that, if successful, this trial will provide us with evidence that Cethrin is more effective than a placebo in tre
'/>"/>